Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

about

Clinical and echocardiographic response of apical vs nonapical right ventricular lead position in CRT: A meta-analysis.

P2860

Q52587214-894A83DB-A4EB-4B70-A042-96A0A5D7D919

P2860

Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

Item

http://www.wikidata.org/entity/Q39037093

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@en

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@nl

type

Item

label

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@en

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@nl

prefLabel

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@en

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@nl

P1476

Co-Morbidities and Cardiac Res ...... They Modify Patient Selection?

@en

P2093

Martin H Ruwald

http://www.w3.org/2001/XMLSchema#string

P2860

Quantification of survival gain from cardiac resynchronization therapy: nonlinear growth with time, and greater gain in low-risk patients, make raw trial data an underestimate of real-world behavior.

Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone.

ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities.

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Associ

Diabetes mellitus and sudden cardiac death: what are the data?

Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators.

2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

The effect of cardiac resynchronization on morbidity and mortality in heart failure.

The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality

P304

1238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4022/JAFIB.1238

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27957175

http://www.w3.org/2001/XMLSchema#string

P932

5135114

http://www.w3.org/2001/XMLSchema#string

Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

about

P2860

P2860

Co-Morbidities and Cardiac Resynchronization Therapy: When Should They Modify Patient Selection?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932